Đột biến R7A trong protein N làm cho kiểu hình nhạy cảm với nhiệt độ của VSV do ảnh hưởng đến sự nhân bản và phiên mã in vitro

Iverson LE, Rose JK (1981) Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 23(2):477–484 Abraham G, Banerjee AK (1976) Sequential transcription of the genes of vesicular stomatitis virus. Proc Natl Acad Sci USA 73(5):1504–1508 Ball LA, White CN (1976) Order of transcription of genes of vesicular stomatitis virus. Proc Natl Acad Sci USA 73(2):442–446 Emerson SU, Wagner RR (1972) Dissociation and reconstitution of the transcriptase and template activities of vesicular stomatitis B and T virions. J Virol 10(2):297–309 Mellon MG, Emerson SU (1978) Rebinding of transcriptase components (L and NS proteins) to the nucleocapsid template of vesicular stomatitis virus. J Virol 27(3):560–567 Morin B, Rahmeh AA, Whelan SP (2012) Mechanism of RNA synthesis initiation by the vesicular stomatitis virus polymerase. EMBO J 31(5):1320–1329 Chen L et al (2013) N-terminal phosphorylation of phosphoprotein of vesicular stomatitis virus is required for preventing nucleoprotein from binding to cellular RNAs and for functional template formation. J Virol 87(6):3177–3186 Hsu CH, Kingsbury DW, Murti KG (1979) Assembly of vesicular stomatitis virus nucleocapsids in vivo: a kinetic analysis. J Virol 32(1):304–313 Rubio C et al (1980) Replication and assembly of VSV nucleocapsids: protein association with RNPs and the effects of cycloheximide on replication. Virology 105(1):123–135 Masters PS, Banerjee AK (1988) Complex formation with vesicular stomatitis virus phosphoprotein NS prevents binding of nucleocapsid protein N to nonspecific RNA. J Virol 62(8):2658–2664 Das T et al (1999) Carboxy-terminal five amino acids of the nucleocapsid protein of vesicular stomatitis virus are required for encapsidation and replication of genome RNA. Virology 259(1):219–227 Barr J et al (1991) Sequence of the major nucleocapsid protein gene of pneumonia virus of mice: sequence comparisons suggest structural homology between nucleocapsid proteins of pneumoviruses, paramyxoviruses, rhabdoviruses and filoviruses. J Gen Virol 72(Pt 3):677–685 Zhang X et al (2008) Role of intermolecular interactions of vesicular stomatitis virus nucleoprotein in RNA encapsidation. J Virol 82(2):674–682 Green TJ et al (2006) Structure of the vesicular stomatitis virus nucleoprotein-RNA complex. Science 313(5785):357–360 Harouaka D, Wertz GW (2009) Mutations in the C-terminal loop of the nucleocapsid protein affect vesicular stomatitis virus RNA replication and transcription differentially. J Virol 83(22):11429–11439 Chen L et al (2015) Several residues within the N-terminal arm of vesicular stomatitis virus nucleoprotein play a critical role in protecting viral RNA from nuclease digestion. Virology 478:9–17 Chen MZ, Ogino T, Banerjee AK (2006) Mapping and functional role of the self-association domain of vesicular stomatitis virus phosphoprotein. J Virol 80(19):9511–9518 Heinrich BS et al (2010) Protein expression redirects vesicular stomatitis virus RNA synthesis to cytoplasmic inclusions. PLoS Pathog 6(6):e1000958 Chuang JL, Perrault J (1997) Initiation of vesicular stomatitis virus mutant polR1 transcription internally at the N gene in vitro. J Virol 71(2):1466–1475 Iseni F et al (2000) Structure of the RNA inside the vesicular stomatitis virus nucleocapsid. RNA 6(2):270–281 Moyer SA et al (1991) Assembly and transcription of synthetic vesicular stomatitis virus nucleocapsids. J Virol 65(5):2170–2178 Harouaka D, Wertz GW (2012) Second-site mutations selected in transcriptional regulatory sequences compensate for engineered mutations in the vesicular stomatitis virus nucleocapsid protein. J Virol 86(20):11266–11275 Chen L et al (2016) Two second-site mutations compensate the engineered mutation of R7A in vesicular stomatitis virus nucleocapsid protein. Virus Res 214:59–64 Regules JA et al (2017) A recombinant vesicular stomatitis virus ebola vaccine. N Engl J Med 376(4):330–341 Geisbert TW et al (2008) Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26(52):6894–6900 Huttner A et al (2015) The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15(10):1156–1166 Liao JB et al (2008) Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein. Clin Vaccine Immunol 15(5):817–824 Marzi A et al (2015) Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg Infect Dis 21(2):305–307 Mire CE et al (2015) Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature 520(7549):688–691 Ryder AB et al (2015) A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. J Virol 89(5):2820–2830 Jayakar HR, Whitt MA (2002) Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology. J Virol 76(16):8011–8018 Stojdl DF et al (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4(4):263–275 Tober R et al (2014) VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J Virol 88(9):4897–4907 Wu L et al (2008) rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther 19(6):635–647